Abstract

BackgroundImmune checkpoint inhibitors (ICIs) particularly those targeting the PD-1/PD-L1 axis have markedly impacted cancer immunotherapy resulting in significant therapeutic responses across an increasingly wide variety of cancers. While obesity is...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call